

## **Shockwave Appoints Laura Francis to Board of Directors**

February 7, 2019

Santa Clara, Calif. – February 7, 2019 – Shockwave Medical, a pioneer in the development and commercialization of Intravascular Lithotripsy to treat complex calcified cardiovascular disease, today announced that Laura Francis has joined its Board of Directors and will serve as Chairperson of Shockwave's Audit Committee.

Ms. Francis currently serves as Chief Financial Officer of SI-BONE, Inc. (Nasdaq; SIBN). Prior to joining SI-BONE, Ms. Francis was the Chief Financial Officer at Auxogyn, Inc., a women's health company, Promega Corporation, a life science reagent company, and Bruker BioSciences Corporation, a public life science instrumentation company. Ms. Francis has also served as Chief Operating Officer and Chief Financial Officer of Nutra-Park Inc., and as Chief Financial Officer of Hypercosm, Inc., a software company. Earlier in her career, Ms. Francis was an engagement manager with McKinsey & Company and an audit manager with Coopers & Lybrand. Ms. Francis received a B.B.A. from the University of Wisconsin and an M.B.A. from Stanford University. She is a Certified Public Accountant (inactive) in the State of California.

## About Shockwave Medical, Inc.

Shockwave Medical is a medical device company focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Shockwave Medical aims to establish a new standard of care for medical device treatment of atherosclerotic cardiovascular disease through its differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque. For more information, visit <a href="https://www.shockwavemedical.com">www.shockwavemedical.com</a>.